SNY News and Press, Sanofi

2024-06-27 07:04:12 ET More on Vigil Neuroscience Biggest stock movers today: BB, MU, and more Augustine Therapeutics raises €17M in series A first closing Seeking Alpha’s Quant Rating on Vigil Neuroscience Historical earnings data for Vigil Neu...

2024-06-27 05:19:29 ET More on related stocks: Micron Technology, Inc. (MU) Q3 2024 Earnings Call Transcript BlackBerry Limited (BB) Q1 2025 Earnings Call Transcript BlackBerry Stock: 4 Considerations Ahead Of Its Q1 2025 Earnings International Paper sinks af...

2024-06-25 14:14:25 ET More on Sanofi Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Sanofi Q1: Wait And See For Now (Downgrade) Sanofi a beneficiary of Alnylam's data on heart drug Amvuttr...

2024-06-25 12:31:58 ET More on CSL CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL Divi...

2024-06-25 11:08:09 ET Eli Lilly and Company ( NYSE: LLY ) said on Tuesday that it is collaborating with Microsoft ( MSFT ) backed-OpenAI that will help leverage generative AI to invent novel antimicrobials to treat drug-resistant pathogens.... Read the full article on See...

2024-06-24 13:25:16 ET More on Sanofi Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Sanofi Q1: Wait And See For Now (Downgrade) Innate falls on updated phase 1/2 data on blood cancer asset...

2024-06-20 15:02:43 ET Summary Novavax, Inc. secured a lucrative deal with Sanofi, receiving potentially $1.2 billion in cash and future royalties for Covid vaccines. The deal significantly improved Novavax's financial position, but the stock has already rallied from $4 to $14, li...

2024-06-20 06:53:11 ET Summary Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well...

2024-06-18 10:05:23 ET Summary Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%. Apogee Therapeutics raised $420 million at $62/share, expanding their financial runway while advancing APG777 into Phase 2 trials....

2024-06-17 12:55:20 ET More on Sanofi, Innate Pharma Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Innate Pharma: Worth A Deeper Look Regeneron, Sanofi win FDA label expansion for ar...